Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study
Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or aflibercept (P = 0.393). The CMT decreased sig...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993624001622 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113660523905024 |
|---|---|
| author | Debdulal Chakraborty Ashish Sharma Soumen Mondal Jay Sheth Tushar Kanti Sinha Subhendu Boral Angshuman Mukherjee Ranabir Bhattacharya Ritobroto Maitra |
| author_facet | Debdulal Chakraborty Ashish Sharma Soumen Mondal Jay Sheth Tushar Kanti Sinha Subhendu Boral Angshuman Mukherjee Ranabir Bhattacharya Ritobroto Maitra |
| author_sort | Debdulal Chakraborty |
| collection | DOAJ |
| description | Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or aflibercept (P = 0.393). The CMT decreased significantly after brolucizumab therapy (P = 0.012), but not with aflibercept (P = 0.284) at 52 weeks. The proportion of patients with IRF and SRF reduced significantly in both arms. The mean number of brolucizumab injections was significantly lower (3.93[±1.28]) than aflibercept (4.75[±1.62]) (P = 0.037) over the 52 weeks. At 52 weeks, 76.67 % of eyes treated with brolucizumab attained full macular dryness (CMT<300 μm with absence of SRF and IRF) compared to 50 % of eyes treated with aflibercept (P = 0.036). Subconjunctival hemorrhage was the only adverse event observed in the study (P = 0.701); no other systemic or ocular adverse events, such as intraocular inflammation, were reported. Conclusion and importance: The BRADIR study suggests that brolucizumab might have an edge over aflibercept in visual and anatomical outcomes that lasted 52 weeks with reduced injection frequency in case of recalcitrant DME. |
| format | Article |
| id | doaj-art-b4091cd6f88a49f09fbd50db2271c7b6 |
| institution | OA Journals |
| issn | 2451-9936 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj-art-b4091cd6f88a49f09fbd50db2271c7b62025-08-20T02:37:05ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362024-12-013610215210.1016/j.ajoc.2024.102152Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR studyDebdulal Chakraborty0Ashish Sharma1Soumen Mondal2Jay Sheth3Tushar Kanti Sinha4Subhendu Boral5Angshuman Mukherjee6Ranabir Bhattacharya7Ritobroto Maitra8Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; Corresponding author. Dept. of Vitreoretinal services; Disha Eye Hospitals; Kolkata, West Bengal, India.Dept of Retina Services, Lotus Eye Hospital and Institute, Coimbatore, TN, IndiaDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, IndiaDepartment of Retina Services, Shantilal Shanghvi Eye Institute (SSEI), Mumbai, IndiaDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, IndiaDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, IndiaDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, IndiaDepartment of MIS, Disha Eye Hospitals, Kolkata, West Bengal, IndiaRadical Health Tech, New Delhi, IndiaPurpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or aflibercept (P = 0.393). The CMT decreased significantly after brolucizumab therapy (P = 0.012), but not with aflibercept (P = 0.284) at 52 weeks. The proportion of patients with IRF and SRF reduced significantly in both arms. The mean number of brolucizumab injections was significantly lower (3.93[±1.28]) than aflibercept (4.75[±1.62]) (P = 0.037) over the 52 weeks. At 52 weeks, 76.67 % of eyes treated with brolucizumab attained full macular dryness (CMT<300 μm with absence of SRF and IRF) compared to 50 % of eyes treated with aflibercept (P = 0.036). Subconjunctival hemorrhage was the only adverse event observed in the study (P = 0.701); no other systemic or ocular adverse events, such as intraocular inflammation, were reported. Conclusion and importance: The BRADIR study suggests that brolucizumab might have an edge over aflibercept in visual and anatomical outcomes that lasted 52 weeks with reduced injection frequency in case of recalcitrant DME.http://www.sciencedirect.com/science/article/pii/S2451993624001622BrolucizumabAfliberceptDiabetic macular edemaVascular endothelial growth factorDiabetic retinopathy |
| spellingShingle | Debdulal Chakraborty Ashish Sharma Soumen Mondal Jay Sheth Tushar Kanti Sinha Subhendu Boral Angshuman Mukherjee Ranabir Bhattacharya Ritobroto Maitra Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study American Journal of Ophthalmology Case Reports Brolucizumab Aflibercept Diabetic macular edema Vascular endothelial growth factor Diabetic retinopathy |
| title | Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study |
| title_full | Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study |
| title_fullStr | Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study |
| title_full_unstemmed | Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study |
| title_short | Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study |
| title_sort | brolucizumab versus aflibercept for recalcitrant diabetic macular edema in indian real world scenario the bradir study |
| topic | Brolucizumab Aflibercept Diabetic macular edema Vascular endothelial growth factor Diabetic retinopathy |
| url | http://www.sciencedirect.com/science/article/pii/S2451993624001622 |
| work_keys_str_mv | AT debdulalchakraborty brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT ashishsharma brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT soumenmondal brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT jaysheth brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT tusharkantisinha brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT subhenduboral brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT angshumanmukherjee brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT ranabirbhattacharya brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy AT ritobrotomaitra brolucizumabversusafliberceptforrecalcitrantdiabeticmacularedemainindianrealworldscenariothebradirstudy |